Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023
Related news for (REUN)
- Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
- Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
- KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
- KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th